Mesoblast to test remestemcel-L in COVID-19 patients; shares up 55% premarket

  • Mesoblast (NASDAQ:MESO) is up 55% premarket after receiving FDA clearance for an Investigational New Drug (IND) application to treat patients with COVID-19 with intravenous infusions of its allogeneic mesenchymal stem cell (MSC) product candidate remestemcel-L.
  • Remestemcel-L is being developed for various inflammatory conditions and is believed to counteract the inflammatory processes.

Read original article here.